Needham Reiterates Buy on Nurix Therapeutics, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a price target of $29.
October 21, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics and maintained a price target of $29, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $29 price target by Needham suggests positive sentiment and confidence in Nurix Therapeutics' future performance. This could lead to increased investor interest and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100